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Background Childhood pneumonia is a major cause
of childhood illness and the second leading cause of
child death globally. Understanding the costs associated with the management of childhood pneumonia
is essential for resource allocation and priority setting
for child health.
Methods We conducted a systematic review to identify studies reporting data on the cost of management
of pneumonia in children younger than 5 years old.
We collected unpublished cost data on non–severe,
severe and very severe pneumonia through collaboration with an international working group. We extracted data on cost per episode, duration of hospital stay
and unit cost of interventions for the management of
pneumonia. The mean (95% confidence interval, CI)
and median (interquartile range, IQR) treatment costs
were estimated and reported where appropriate.
Results We identified 24 published studies eligible for
inclusion and supplemented these with data from 10
unpublished studies. The 34 studies included in the
cost analysis contained data on more than 95 000 children with pneumonia from both low– and–middle income countries (LMIC) and high–income countries
(HIC) covering all 6 WHO regions. The total cost (per
episode) for management of severe pneumonia was
US$ 4.3 (95% CI 1.5–8.7), US$ 51.7 (95% CI 17.4–
91.0) and US$ 242.7 (95% CI 153.6–341.4)–559.4
(95% CI 268.9–886.3) in community, out–patient facilities and different levels of hospital in–patient settings in LMIC. Direct medical cost for severe pneumonia in hospital inpatient settings was estimated to be
26.6%–115.8% of patients’ monthly household income in LMIC. The mean direct non–medical cost and
indirect cost for severe pneumonia management accounted for 0.5–31% of weekly household income.
The mean length of stay (LOS) in hospital for children
with severe pneumonia was 5.8 (IQR 5.3–6.4) and 7.7
(IQR 5.5–9.9) days in LMIC and HIC respectively for
these children.
Conclusion This is the most comprehensive review to
date of cost data from studies on the management of
childhood pneumonia and these data should be helpful for health services planning and priority setting by
national programmes and international agencies.
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the Wiley Online Library) for the period 1 January 1998 to
October 31 2013. (for search strategy, see Appendix S1 in
Online Supplementary Document).

Pneumonia is one of the leading causes of morbidity and
mortality in children under–five globally, and accounted for
about 935 000 (15%) deaths in 2013 and 120 million new
episodes of illness in this age group in 2010 [1,2]. Appropriate management of childhood pneumonia can reduce
pneumonia–specific mortality by 32–72% [3–5] and thus
accelerate the progress toward achievement of the Millennium Development Goal 4 (MDG4). Childhood pneumonia
places a large economic burden on families and the health
care system, especially in resource–constrained low– and
middle–income countries (LMIC). Severe ALRI is a substantial burden on health services worldwide and a major cause
of hospital referral and admission in young children [6]. Although several studies in high–income as well as low– and
middle–income countries have reported the costs associated with an episode of pneumonia (at the individual patient level), there are no published systematic reviews summarizing the evidence from different health systems and
settings globally. Bahia et al reviewed pneumococcal disease
costs and productivity loss in Latin America and the Caribbean showed variation in unit costs of pneumococcal pneumonia at outpatient and inpatient levels [7]. We aimed to
conduct a systematic review of published data on the costs
associated with management of pneumonia episodes in children younger than 5 years and to identify unpublished data
sets from pneumonia research groups globally. Cost estimates based on these data should be useful to develop models for estimating cost of management of pneumonia in
community as well as hospital–based settings.

Three review authors (SZ, PS, IK) independently selected
potentially relevant studies based on their title and abstract.
Any disagreements in study selection or data extraction
were resolved after discussion with SZ and HC. The eligible
studies were retrieved electronically for full–text review. We
included studies that investigated all–cause pneumonia in
a non–selective population sample, reported empirical cost
data for pneumonia treatment (using any intervention including, but not limited to, antibiotics), and included only
children younger than 5 years or reported data separately
for this age group. We excluded review articles, vaccine
cost–effectiveness trials, and studies considering specially
selected cohorts with severe co–morbidity (Appendix S2
in Online Supplementary Document). We developed and
piloted a comprehensive data extraction template. We collected data on cost per episode, cost and unit cost of medication and services, duration of hospital stay and direct
medical and non–medical costs. Direct medical cost included costs related to medication, diagnostic tests, medical staff time and hospital stay. Direct non–medical costs
included those relating to food, transportation and accommodation charges. Any additional data on indirect costs
such as care–givers’ time and earning loss were also recorded, where available. Additionally, we extracted data on
study characteristics including country, treatment setting,
study type and sample size. We recorded the cost study
perspective only if explicitly stated in the text of the article
to avoid subjective influence. For those papers that did not
explicitly state the perspective used, we noted “–“ for “unstated”.

METHODS
Review of published studies
We aimed to identify all published studies reporting empirical cost data on the treatment of episodes of pneumonia
in children aged below 5 years during a 15–year period
(1998–2013). We included studies in children younger
than 5 years with pneumonia managed as in–patients or
out–patients (using standard treatment per local standard)
in secondary and tertiary hospitals, first level facility or in
community settings. Data on the cost of a single episode of
severe pneumonia from the societal and health care perspectives were collected as the primary study outcome. We
developed a review protocol at the beginning of this study
and followed the same throughout the process.

We classified countries into high income and low–and–
middle income categories based on the classification adopted by the World Bank and according to 2012 Gross National Income (GNI) per capita, calculated using the World
Bank Atlas method. The groups are low–income per capita US$ 1035 or less; lower middle–income US$ 1036–US$
4085; upper middle income US$ 4086–US$ 12 615; and
high income US $12 616 or more [8].

Quality assessment
We assessed the quality of the included studies using a 13
point scale based on a modified Drummond checklist [9]
for economic evaluation focusing on the methodological
robustness and detail of reporting (Appendix S3 in Online
Supplementary Document). Studies were considered
high quality if more than 10 points were addressed, medium quality studies covered 7–9 points and low quality
studies addressed less than 6 points. Studies with all quality levels were included in the final analysis.

We undertook a systematic literature review with three reviewers (PS, IK, SZ), and hand searched reference list of all
included articles. We searched four databases (with online
search tools) to offer maximum coverage of the relevant literature: Medline, EMBASE, The Centre for Review and Dissemination Library (incorporating the DARE, NHS EED,
and NHS HTA databases); and The Cochrane Library (via
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Unpublished data collection

nia need for hospital admission based on physician’s assessment); severe pneumonia at community level (based on
assessment by a trained health worker at home/first level
facility using WHO IMCI (2005) case definition); and non–
severe pneumonia at outpatient level (defined as fast
breathing for age in children aged 2 to 59 months). The
costing model included direct medical cost, direct non–
medical cost and indirect costs. We calculated the cost per
episode based on the estimates of the unit cost per contact
(eg, unit cost of an antibiotic per day) at each management
level multiplied by the resource utilization proportions (eg,
80% of children took amoxicillin for 5 days), plus indirect
costs. For the mean total cost of treatment per episode we
summed the cost of drugs, diagnostic investigations and
hospital stay, as well as transportation and opportunity cost
for caregivers’ time. The formula is given in Figure 1.

We collected unpublished data from 10 collaborating sites
that were part of a Severe ALRI Working Group (SAWG)
[6]. The study population included children under 5 years
of age with a clinical diagnosis of pneumonia. We defined
pneumonia using the World Health Organization’s (WHO)
Integrated Mangement of Childhood Illness (ICMI) definition by three different severity categories: non–severe, severe and very severe pneumonia based on WHO pocket
book for hospital care for children 2005 [10]. We included
all interventions for pneumonia management as detailed in
the WHO pocket–book (for community/and facility–based
management) where data were available.
We designed a costing spreadsheet with detailed descriptions of case definitions and methods and used this for data
collection. Actual cost of medications, supplies, personnel
and average laboratory costs were collected. Methods used
to gather primary cost data in these studies were recorded
in the spreadsheet. Resource utilization data from patient
records were also documented, where available, including
length of stay in hospital, the quantity of drugs and supplies utilized by each patient, and the use of diagnostic tests
and procedures. We also attempted to collect data on out–
of–pocket spending (by patients) on transport and food
where possible. Indirect cost of caregivers’ time and daily
pay rate were also recorded. Primary data collection was
conducted using the provided standardized templates and
guidelines at individual study site. (Appendix S4 in Online
Supplementary Document).

We reported all cost data in 2013 US$ equivalent prices.
We first converted all costs to US$ and then adjusted for
inflation to 2013 values. Conversions were made using the
Penn World Tables 8.0 (http://www.ggdc.net/pwt) and an
online inflation–calculating tool (http://usinflation.org/cpi–
inflation–calculator) on 20th October 2013.

Statistical analysis
We have stratified the cost results by country income category: high–income countries (HIC) and low– and middle–
income countries (LMIC). As an important input in the costing analysis for in–patient management, length of stay (LOS)
in hospital was extracted for severe hospitalized cases. Cost
per episode, cost by component (direct medical, direct non–
medical and indirect costs), and percentage of total cost per
episode in each component were summarized. Cost per episode was synthesized by severity of diseases in each strata.
The mean with 95% CI of the treatment costs and the median with interquartile range (IQR) of LOS were estimated
and reported where appropriate. The 95% CIs were calculated based on 5000 bootstrap samples. Mean and median
values were compared using appropriate statistical tests.

We used a bottom–up approach to calculate cost per episode for each level of the intervention (community, first
level health facility and hospital). Costs were calculated and
presented separately based on severity and service delivery
channels: very severe pneumonia at hospital level (defined
as pneumonia with central cyanosis, inability to breastfeed
or drink, or vomiting everything, convulsions, lethargy or
unconsciousness and severe respiratory distress diagnosed
by doctor or physicians using WHO IMCI (2005) case definition or pneumonia cases requires critical care); severe
pneumonia at hospital level (defined as pneumonia with
chest indrawing using WHO IMCI definition or pneumo-

Direct medical cost in studies reported from household
perspective were compared with monthly household income in respective countries to evaluate the burden on

Figure 1. Formula for the mean total cost of treatment per episode.
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tion and analysis. The key reasons for exclusions included:
no data for children below 5 years or no cost data on pneumonia management were reported. For unpublished studies,
we contacted 16 sites, 10 of which had data that met our
eligibility criteria and contributed to the analysis. The unpublished cost data were for the period January 2001 to August 2012. Six of these sites provided cost data using a template and guidelines designed for this project while the
remainder provided unpublished data in their own formats.

families. Monthly household incomes were derived from
Gallup World Poll using annual median household income
divided by 12 months [11]. These income results were
based on Gallup data gathered between 2006 and 2012 in
131 populations. In two countries which annual household
income data was missing, we used GNI per capita from
World Bank database times the mean number of people per
household instead. The percentages of direct non–medical
costs and indirect cost per episode of weekly household
income were also assessed to show the economic impact of
pneumonia management for families when direct medical
cost was not considered.

Characteristics of published and
unpublished data
We identified 24 studies from the literature review and collected additional 10 data sets of unpublished studies totalling 34 studies from 21 countries across the 6 WHO regions (Table 1). Over 60% of the studies (21 out of 34)
were conducted in the South East Asia and Africa Regions.
The included studies reported data from a variety of treatment settings: community, out–patient and in–patient care
settings in primary, secondary and tertiary hospitals, and
at city, district, provincial and national levels. Twenty–seven of the 34 studies were stand–alone primary cost analysis and/or cost–of–illness studies. The remaining 7 studies
were designed to collect cost data alongside clinical trials
or epidemiological studies.

We conducted all data analyses using SPSS v.19 (IBM, New
York City, NY, USA) noting that included studies showed
marked heterogeneity of population, methodology, treatment procedure reporting categories and perspectives.

RESULTS
Search results
We identified 789 studies through database searching, of
which 60 articles were eligible for full text review on the basis of title and abstract assessment (Figure 2). Subsequently,
only 24 papers were identified to be eligible for data extrac-

Records identified through database
searching after duplicates removed
(n = 789)

Records titles and
abstracts screened
(n = 789)

Records excluded with
reasons
(n = 729)

Full-text articles assessed
for eligibility
(n = 60)

Full-text articles excluded,
due to no pneumonia specific
cost data or no data for children
under 5 years old

(n = 36)

Studies included in
quantitative synthesis
(n = 24)

Figure 2. PRISMA flow diagram for severe pneumonia cost systematic review.
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Table 1. Characteristics of all studies included*
WHO

Country, publication year Study population

region

Healthcare

Severity

setting

of

Study design

Source of case

Perspective

definition

Sample Mean (SD) / Data
size

median age

pneumonia

of patients

studied

(months)

source

EUR

AMR

WPR

Northern Ireland,
1999 [39]1

Antrim
(urban)

H2

S

QES

PD

Spain, 2013 [17]

Barcelona
(urban)

H3

S, VS

Cost analysis‡

Culture–proved Healthcare
pneumonia

Germany, 2005 [16] National

O,H1

S, VS

Cost–of–illness PD

Chile, Uruguay,
2007 [12]

National

O,H1

S, NS

Cost analysis‡

United States,
2012*

Denver,
Colorado
(urban)

H3

S, VS,
NS

Australia, 2008 [15]

National

O, H1–3

Australia, 2008 [14]

Melbourne,
Victoria
(urban)

Australia, 2011*

Sydney
(urban)

45

39.60
(16.8)

H

101

39.60

H

Societal

402

N/A

N, IQ

Healthcare

366

N/A

H,IQ

Cost–of–illness PD by WHO
Societal
IMCI definition

940

0–59

H, P

S

Cost analysis‡

ICD–10

Healthcare

1348

N/A

N

O,H1

S

Cohort study/
cost–of–illness

Health
professional’s
diagnosis

Societal

528

N/A

N,H,IQ,
Pilot

H3

S, VS

Cost–of–illness PD by WHO
Societal
IMCI definition

N/A

N/A

P,
Market
price

90

5.00

IQ

PD, ICD–10

N/A–

Low– and middle–income countries (number of studies = 27)
Dhaka (urban) H3

S

Cost–of–illness PD

Bangladesh, 2005†

Dhaka (urban) H3

S, VS

Cost–of–illness PD by WHO
Household
IMCI definition

114

70.32

IQ

Bangladesh, 2010
[24]

Mirpur, Dhaka O, H2
(urban)

S

RCT/CEA

PD by WHO
Societal
IMCI definition

360

8.00

–

Bangladesh, 2010†

Barishal,
Bogra,
Comilla,
Kishoregonj
(urban)

S, NS

Cost–of–illness PD by WHO
Societal
IMCI definition

235

N/A

IQ

Bangladesh, 2012†

Mohakhali,
H3
Dhaka (urban)
Vellore (rural) H1, H2

S, VS,
NS
S

Societal

340

N/A

H

8.8

H, IQ

H3

S

Healthcare/
Household
Societal

56

Berhampur,
Orissa (urban
and rural)
Lombok
(rural)
Peshawar city
(urban)
Ghizer district
(rural)
Ghizer district
(rural)
Matiari (rural)

Cost–of–illness PD by WHO
IMCI definition
Cost–of–illness PD by WHO
IMCI definition
Epidemiologi- PD
cal study

52

N/A

H, IQ

H3

S

H3

S

O, H1,
H2
O, H1,
H2
C

S, NS

Haripur
district (rural)

C, H1, H2 S

SEAR Bangladesh, 2010
[26]

India, 2009 [30]
India, 2002 [29]

Indonesia, 2001†
Pakistan, 2003 [25]
Pakistan, 2006 [20]
Pakistan, 2008 [19]
Pakistan, 2010†
Pakistan, 2012 [23]

H3

Viet Nam, 2010 [18] Nha Trang city H2
(urban)
C, O, H1
Viet Nam, 2001 [28] Ba Vi district
(rural)

www.jogh.org
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S, VS,
NS
S

S, VS,
NS
S

Family

Cost–of–illness PD by WHO
Societal
IMCI definition
RCT/CEA
PD by WHO
–
IMCI definition
Cost analysis‡ PD
Societal

N/A

N/A

H

126

N/A

–

502

N/A

IQ

Cost analysis‡

Healthcare

141

N/A

IQ

Healthcare

N/A

N/A

Household

423

N/A

Surveillance
H, IQ

Healthcare

788

12.67

N, H

Household

94

N/A

IQ

PD by WHO
IMCI definition
Cost–of–illness PD by WHO
IMCI definition
Cost analysis‡ WHO
definition by
health worker
Cost–of–illness PD by WHO
IMCI definition
Cost analysis‡ WHO
definition,
self–reported
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Table 1. Continued
WHO

Country, publication year Study population

region

Healthcare

Severity

setting

of

Study design

Source of case

Perspective

definition

Sample Mean (SD) / Data
size

pneumonia

VIEWPOINTS
Papers

Guinea, 1998 [21]
South Africa, 2011
[33]
South Africa, 2012
[22]
South Africa, 2001†
Kenya, 2009 [32]
Zambia, 2009 [31]

(months)

AMR

Colombia, 2013
[27]

Brazil, 2011†
Argentina, 2012†

WPR

Brazil,2007 [12]
Fiji, 2012 [34]

EMR

Jordan, 2010 [35]

National
Pretoria
(urban)
National

O, H1
H3

S, NS
S, VS

CEA
Cost analysis‡

H3

RCT

Soweto
(urban)
National

H3

S, VS,
NS
S, VS

Kanyama
Township
(urban)
National

Goiânia
(urban)
Buenos Aires
(urban)
National
Viti Levu
(urban and
rural)
Amman

source

of patients

studied

AFR

median age

PD
WHO
definition
PD

–
–

73650 N/A
3014 N/A

H, E
H

Societal/
health care
Societal

745

N/A

H, IQ

509

14.00

H,IQ

S

Cost–of–illness PD by WHO
IMCI definition
Cost analysis‡ PD
Societal

205

12.00

H, IQ

S

Cost analysis‡

PD

Healthcare

9146

N/A

N,H,P,W

H1,H2,H3 S, VS,
NS

Cost–of–illness§

Healthcare

1545

N/A

I

H3

S, VS

Societal

79

0–36

H, N

H3

S, VS

Societal

N/A

N/A

N

O,H1
O

S, NS
S

Cost–of–illness§
Cost–of–illness§
Cost analysis‡
Cost analysis‡

WHO
definition,
radiographically diagnosed
PD by WHO
IMCI definition
PD by WHO
IMCI definition
PD, ICD–10
PD by WHO
IMCI definition

Healthcare
Societal/
household

366
390

N/A
N/A

H,IQ
N,H, IQ

H1

S

Cohort study

PD

–

728

4.30

N/A

H3, H2,
H1
O,H2

*Severity of pneumonia: NS – non severe, S – severe, VS – very severe. Data source: H – hospital records, N – national data, IQ – interviews and questionnaires, I – insurance database, P – pharmacy database, W – WHO database. Treatment settings: H3 – tertiary hospital in–patient, H2–secondary
hospital in–patient, H1 – primary hospital inpatient, O – out–patient care, C – community ambulatory care; PD – physician’s diagnosis, CEA – cost effectiveness analysis, RCT – randomized clinical trial, QES– quasi–experimental study, N/A – not available, PD – physician’s diagnosis, IMCI – Integrated
Management of Childhood Illness, WHO – World Health Organization, SD – standard deviation.
EUR – Europe Region, AMR – the Americas Region, WPR – Western Pacific Region, SEAR – South East Asia, AFR– The Africa Region, EMR– Eastern
Mediterranean Region
†Unpublished data.
‡The analysis of the comparative costs of alternative treatments or health care programmes.
§The cost analysis of treatment of a disease.

The included studies reported cost data on a total of 97 062
children treated at facility or community levels, with a median sample size of 378 (IQR 117–741) across all studies.
The age of the participants was reported in 12 studies and
the median age was 12.3 months (IQR 8.20–33.20). The
perspective of costing was explicitly stated in 30 of 34 studies. Of these, the most common perspectives were societal
(16 out of 33, 1 study did not specify perspective), health
care (11 out of 33) and household (5 out of 33). In most
studies, the sources of pneumonia case definition were
physician’s diagnosis according to WHO IMCI definition
(29 out of 34), culture–proved pneumonia was used for
case definition in 1 study, self–reported condition according to WHO IMCI definition was adopted in one study, and
two studies used health workers’ diagnosis. A number of
different sources were used for gathering cost data, the
most common being through hospital records and costing

June 2016 • Vol. 6 No. 1 • 010408

interviews/questionnaires. Interviews and questionnaires
were commonly used in studies with a household perspective to collect data on indirect costs. Other sources included a national database of costs, insurance databases, surveillance data and pharmaceutical databases. The WHO
CHOICE database, expert opinion and data from pilot
studies were also used to collect data on the unit cost of
pneumonia treatment.
The average quality score of 24 published studies was 8.21
out of 13 on scale based on modified Drummond checklist
(range 3–12) (Appendix S5 in Online Supplementary
Document). The majority of the studies failed to consider
discounting and did not perform sensitivity analyses. There
were 6 studies considered high quality, 14 studies were medium quality, and 4 low quality studies. All studies were
included into the final analysis.
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Cost of management per episode of
pneumonia
Cost results stratified by income category are presented in
Table 2, Table 3 and Figure 3. In HICs, the mean cost of
treatment for an episode of severe pneumonia at the hospital out–patient level was US$ 251.1 in Germany [16]. An
Australian study [14] reported similar cost of US$ 254.9
for community management of severe pneumonia. Average
costs of facility based case management for young children
admitted in primary/sary and tertiary hospitals were US$
2803.5 (95% CI IQR 2000.6–3683.3), and US$ 7037.2
(95% CI 4028.6–11 311.0) respectively, which was 11–28
fold higher than in those managed as out–patients. The total cost per episode for the management of non–severe
pneumonia at out–patient level was also reported for three
countries: US$55.8 in Uruguay [12], US$ 272.7 in Chile
[12] and US$ 334.6 in the United States [36]. The cost for
very severe pneumonia managed in general pediatric wards
followed by intensive care unit (ICU) care was reported to
be US$9151.3 in a tertiary hospital in Spain [17] and US$
120 576.3 in the United States, which is nearly 2–17 fold
of the cost for severe pneumonia management in hospital

In LMICs, the cost of case management for severe pneumonia was reported across all treatment settings. The community management cost was only reported in studies conducted in South–East Asia region, with a mean cost of US$ 4.3
(95% CI 1.5–8.7) per episode. Out–patient care mean costs
were US$ 51.7 (95% CI 17.4–91.0) per case. Costs for in–
patient care varied by regions, level of hospitals (primary/
sary/tertiary), and levels of care offered at a facility: the mean
cost for primary/sary hospital care was 242.7 (95% CI
153.6–341.4) and for tertiary/teaching hospital was 559.4
(95% CI 268.9–886.3). Two groups–severe pneumonia by
WHO IMCI definition and hospitalized pneumonia by physician’s diagnosis–showed similar costs in all levels of care.
The in–patient care costs were 4–11 fold greater than that
for out–patient care in the LMICs strata, which in turn was
significantly higher than that for community management.

Table 2. Cost per episode for childhood pneumonia management in high–income countries
Severity

WHO

Country, publication year Perspective

region

Sample Cost per episode (2013 US$)

cost per episode

Tertiary/teaching
hospital in–patient
care
US, 2012*
Societal
Healthcare
Chile, 2007 [12]
Uruguay, 2007 [12] Healthcare
Non–severe pneumonia mean cost (95% CI)
Severe
Healthcare
AMR Chile, 2007 [12]
pneumonia
Uruguay, 2007 [12] Healthcare
by WHO
US, 2012*
Societal
IMCI
EUR North Ireland, 1999 NA
Definition
[13]
WPR Australia, 2011*
Societal
Hospitalised WPR Australia, 2008 [14] Societal
pneumonia
Australia, 2008 [15] Healthcare
EUR Germany, 2005 [16] Societal
Spain, 2013 [17]
Healthcare
Severe pneumonia mean cost (95% CI)
Non–severe
pneumonia

AMR

Very severe AMR US, 2012*
Societal
pneumonia
by IMCI
Healthcare
Very severe AMR Spain, 2013 [17]
pneumonia
requiring
critical care
Very severe pneumonia mean cost (95% CI)

Cost component, % of total

size

940
366
366
366
366
940
45

15 029.2
5733.8, 2716.8

NA
528
1348
402
101

6,259.1

Secondary/
primary
hospital
in–patient care

Out–
ComDiDirect Indipatient muni- rect
non–
rect
care
ty care med- medical
ical
334.6
272.7
55.8
221.0 (55.8–334.6)
4316.7
100
1421.6
100
100

2813.1
2307.8
3158.6

940

5447.3
7037.2
(40 286–11 311.0)
120 576.2

101

9151.3

2803.5
(2000.6–3683.3)

254.9
251.1
251.1

93.1
100
100
41.5
100

6.9

19.5

38.5

254.9

64 863.8 (9151.3–120 576.3)

NA – Information not available, EUR – Europe Region, AMR – The Americas Region, WPR – Western Pacific Region, CI – confidence interval, IMCI –
Integrated Management of Childhood Illness
*Unpublished data.
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settings in HICs. The majority of studies from HIC took
only direct medical costs into consideration. Only two
studies included direct non–medical costs and indirect
costs [16]. The mean proportion of the total cost for direct
medical, direct non–medical and indirect costs were
41.5%, 19.5% and 38.5% respectively.
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Table 3. Cost per episode for childhood pneumonia management in low– and middle–income countries
Severity

WHO Country, publication year

Perspective

region

Sample

Cost per episode (2013 US$)

total cost per episode

VIEWPOINTS
Papers

Tertiary/teaching
hospital
in–patient care
Non–severe SEAR Viet Nam, 2010 [18]
pneumonia
Pakistan, 2008 [19]
Pakistan, 2006 [20]
Bangladesh, 2012*
AFR Guinea, 1998 [21]
South Africa, 2012 [22]

Healthcare
Healthcare
Societal
Societal
NA
Societal/
health care
AMR Brazil, 2007 [12]
Healthcare
Non–severe pneumonia mean cost (95% CI)
SEAR Pakistan, 2010*
Healthcare
Severe
pneumonia
Pakistan, 2012 [23]
Household
by WHO
Bangladesh, 2012*
Societal
IMCI
Bangladesh, 2010 [24] Societal
Definition
Viet Nam, 2010 [18]
Healthcare
Pakistan, 2008 [19]
Healthcare
Pakistan, 2003 [25]
NA
Bangladesh, 2005*
Household
Bangladesh, 2010 [26] Household
Indonesia, 2001*
Societal
AFR Guinea, 1998 [21]
NA
South Africa, 2001*
Societal
AMR Brazil, 2007 [12]
Healthcare
Brazil, 2011*
Societal
Colombia, 2013[27]
Healthcare
Argentina, 2012*
Societal
Hospitalised SEAR Viet Nam, 2001 [28]
Household
pneumonia
Pakistan, 2006 [20]
Societal
India, 2009 [29]
Healthcare/
household
India, 2002 [30]
Societal
AFR Zambia, 2009 [31]
Healthcare
Kenya, 2009 [32]
Societal
South Africa, 2011 [33] Societal
South Africa, 2012 [22] Societal/
health care
WPR Fiji, 2012 [34]
Societal/
household
AMR Colombia, 2013 [27]
Healthcare
EMR Jordan, 2012*
NA
Severe pneumonia mean cost (95% CI)
Very severe
pneumonia
by IMCI

788
141
502
340
73 650
745

Secondary/ Out–patient Commu- Direct Direct Incare
nity care medi- non– diprimary
cal
medi- rect
hospital
cal
in–patient care
28.6
29.4
94.1–17.8
5.7
3.2
263.1

366
NA
423
340
360
788
141
126
114
90
NA
73650
509
366
79
1545
NA
94
502
56
52
9146
205
509
745

93.0
66.9 (21.7–129.7)
7.9
5.7
124.0

193.6

1545
728

340
788
141
3014

South Africa, 2012 [22] Societal/
health care
AMR Colombia [27]
Healthcare
Very severe pneumonia mean cost (95% CI)

745
1545

8.7
1.5

20.3
80.6†
124.2
135.2
480.9§
1474.1†,‡

62.6#

110.6
110.0
461.0
594.5#
517.6

1648.0
2.7
145.7

310.8
44.7

127.6

249.7
162.1, 89.5

55.7

23.9
236.8
491.4†, 1553.2‡
1223.1

25.7, 15.6
304.4
76.2
563.4
559.4
242.7
51.7
4.3
(268.9–886.3) (153.6–341.4) (17.4–91.0) (1.5–8.7)
15.7
61.2
81.3
849.0†
14795.4‡
6696.2
3643.4
6496.0
(2246.2–12007.4)

71.3
(61.2–81.3)

100
89.1
Y
Y
64.1
100
70.9†
67.6
75
69

39.5
186.0

390

Societal
Healthcare
Healthcare
NA

Very severe
pneumonia
requiring
critical care

SEAR Bangladesh, 2012*
Viet Nam, 2010 [18]
Pakistan, 2008 [19]
AFR South Africa, 2011 [33]

Cost component, % of

size

100
94†
100
100
56–88
45.3
45.7

1.3

9.6

Y
Y
35.9

Y

29.1†
32.4
25
30

1†

5†

Y
55
5.3

47.4

100
100
86
100
98

14

Y

2

0.2

61.9

33.2

4.9

100

15.7
(15.7–15.7)

NA – information not available, Y – authors considered the cost component, but the proportion was unknown, EUR – Europe Region, AMR – The Americas Region, WPR – Western Pacific Region, SEAR – South East Asia, AFR – The Africa Region, EMR – Eastern Mediterranean Region
*Unpublished data.
†Public health care.
‡Private health care.
§Pediatric ward.
#Supplementary health system.
June 2016 • Vol. 6 No. 1 • 010408

8

www.jogh.org

• doi: 10.7189/jogh.06.010408

PAPERS
VIEWPOINTS

Cost of managing severe pneumonia in young children

Figure 3. Range of cost per episode for
pneumonia management (2013 US$).

The costs for management of non–severe pneumonia managed at outpatient level were US$ 66.9 (95% CI 21.7–
129.7), which was slightly higher than for severe cases at
outpatient level. This is because the hospital short stay for
non–severe pneumonia in South Africa [22] was relatively
high at US$ 263.1 per episode. The mean cost for very severe cases was US$ 6496.0 (2246.2–12 007.4), which is
nearly 10-fold of severe case management cost.

only 0.4%–4.1% of family’s monthly income indicating decreased burden in these settings. (Table 4).
Of the papers reporting cost component of severe pneumonia management, direct medical cost was reported across all
studies and accounted for 45%–100% of the total cost. The
mean direct non–medical cost and indirect cost were US$
22.0 (11.8–32.7) and US$ 27.0 (4.0–54.3) respectively,
which account for 0.5%–31.0% of weekly household income (Table 5).

There were 6 studies reporting cost from household perspective, mainly from LMICs in South East Asia Region.
Direct medical cost for severe pneumonia in hospital inpatient settings were 26.6%–115.8% of the monthly household income, thus demonstrating that severe pneumonia
management in hospital placed a significant financial burden on families. On the other hand, outpatient and community management of severe pneumonia accounted for

Length of stay in hospital
The in–patient cost was determined primarily by the length
of stay (LOS) and the average cost per bed day. In this review, we extracted length of stay for severe pneumonia for
future costing analysis reference (Tables 6–8).

Table 4. Direct medical cost for severe pneumonia management in low– and middle–income countries reported from household
perspective
Country, publication year

Direct medical cost (2013 $US; % of direct medical cost to monthly household income)

Bangladesh, 2010 [26]
Bangladesh, 2005†
India, 2009 [30]
Pakistan, 2012 [23]
Viet Nam, 2001 [28]
Fiji, 2012 [34]

Tertiary/teaching
Secondary/primary
Hospital in–patient care hospital in–patient care
124.2 (52.9%)
–
80.6‡ (34.3%)
62.6§ (26.6%)
305.8 (115.8%)
135.1 (64.7%)
–
–
–
–
–
–

Out–patient care
–
–
7.9 (2.3%)
–
25.7 (4.1%)/15.6 (2.5%)

Monthly household
income (2013 $US)*
Community
ambulatory care
–
–
–
1.5 (0.4%)
2.7 (0.7%)
–

234.9
234.9
264.0
338.3
398.6
632.5‡

*Monthly household income (2913 US$) were derived from Gallup World Poll annual median household income, equals annual median household
income divided by 12. These results were based on Gallup data gathered between 2006 and 2012 in 131 population. Source: http://www.gallup.com/
poll/166211/worldwide-median-household-income-000.aspx.
†Numbers used GNI per capita based on purchasing power parity (PPP) due to lack of monthly household income data. Source: http://data.worldbank.
org/indicator/NY.GNP.PCAP.PP.CD/countries.
‡Public health care.
§Supplementary health system.
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Table 5. Direct non–medical cost and indirect cost per episode for severe pneumonia management in low– and middle–income
countries

VIEWPOINTS
Papers

Country, publication year

Direct non–medical cost*

Bangladesh, 2010 [24]
India, 2002 [29]
Pakistan, 2008 [19]
Pakistan, 2006 [20]
Pakistan, 2012 [23]
Kenya, 2009 [32]
Guinea, 1998 [21]
South Africa, 2012 [22]
Fiji, 2012 [34]
Brazil, 2011*
Mean (95% CI)
Median (IQR)

Total
32.4
5.3
35.9
55.0
3.3
14.0
30.0
2.0
33.2
9.7
22.0 (11.8–32.7)
22.0 (4.6 –33.9)

Transportation

Food

5.3
12.2

23.7

2.3

1.0

Indirect cost†

% of non–medical cost to

Total

monthly household income

Monthly household
income (2013 US$)

13.8%
2.0%
10.6%
16.3%
1.0%
9.0%
31.0%
0.5%
5.3%
1.6%

234.9
264.0
338.3
338.3
338.3
155.8
96.7‡
434.8
632.5‡
626.8

47.5

9.6

1.4
33.2
8.41
1.31
10.5 (3.5–22.3) 8.7 (1.0–23.7)
6.9 (2.1–11.5) 1.3 (–)

0.2
4.9
73.1
27.0 (4.0–54.3)
9.6 (2.5–60.3)

CI – confidence interval, IQR – interquartile range
*Direct medical costs include medications and consultation, non–medical cost includes transportation, food and accommodation.
†Indirect cost refers to parental loss of earnings in the period of illness. Monthly household income (2013 US$) was derived from Gallup World Poll
annual median household income, equals annual median household income divided by 12. These results were based on Gallup data gathered between
2006 and 2012 in 131 populations. Source: http://www.gallup.com/poll/166211/worldwide-median-household-income-000.aspx.
‡Numbers used GNI per capita based on purchasing power parity (PPP) due to lack of monthly household income data. PPP GNI is gross national income (GNI) converted to international dollars using purchasing power parity rates. An international dollar has the same purchasing power over GNI as
a US dollar has in the United States. GNI is the sum of value added by all resident producers plus any product taxes (less subsidies) not included in the
valuation of output plus net receipts of primary income (compensation of employees and property income) from abroad. Source: http://data.worldbank.
org/indicator/NY.GNP.PCAP.PP.CD/countries.

Table 6. Length of stay of very severe pneumonia and severe

Unit cost of case management

pneumonia in hospital in high–income countries

Country and year

Setting

LOS (SD) days

Unit cost of treatment and resource uptake should be routinely reported in cost studies. However, only 13 of the 34
included studies reported these data. Since treatment protocols (use of antibiotics, diagnostic tests, procedures and
levels and intensity of care) varied between studies, this
contributed to variations in costs across studies. For example, the average cost of chest radiograph in LMIC was US$
8.4 (95% CI 4.3–27.0), which was significantly lower than
US$ 185.5 (95% CI 66.3–357.7) in high income countries
(Table 9). We attempted to abstract unit cost data but were
unable to include it in the presented direct medical costs
because of paucity of information.

Sample
size

Very severe pneumonia:
Germany, 2005 [16] ICU
Spain, 2013 [17]
ICU
USA, 2012*
ICU
Australia, 2011*
ICU
Median (IQR)
Severe pneumonia:
Ireland, 1999 [13]
Control group
New treatment group
Germany, 2005 [16] Hospitalised cases
Australia, 2008 [14] Without impact diary
With impact diary
Australia, 2011*
Non–ICU
Spain, 2013 [17]
Non–ICU
USA, 2012*
Non–ICU
Median (IQR)

7.4 (6.1)
18.0
18.3 (43.1)
11.0
14.5 (10.1–18.1)

2039
99
1116
–

8.3 (7.7–9.0)
4.0 (3.5–4.6)
7.4 (6.1)
8.8
13.5
6.0
10.5
2.7 (2.3)
7.9 (5.5–9.2)

44
45
2039
202
523
–
99
940

DISCUSSION
This is the first attempt to conduct a systematic review of
all published and available unpublished cost data on the
management of childhood pneumonia. Costs per episodes
in HICs were 5–13–fold higher in all delivery channels
than those in LMICs. The review demonstrates that the
magnitude of cost per episode increases markedly as the
level of treatment delivery rises. Community management
for severe pneumonia was less than 10% that of the cost of
out–patient management among all levels of management
in LMICs. Thus, there are strong economic reasons for considering community case management as a central strategy
for pneumonia case management in low income countries;
this merits further evaluation which should include consideration of medical outcomes. The mean lengths of stay

IQR – interquartile range, ICU – intensive care unit
*Unpublished data.

The mean LOS for severe pneumonia reported in individual studies ranged from 4–13.5 days, with a mean LOS 7.7
(95% CI 5.5–9.9) days and median 7.9 (IQR 5.5–9.2) days
in HIC, and mean LOS 5.8 (95% CI IQR 5.3–6.4) days and
median 6.4 (IQR 4.1–7.1) days in LMIC. For very severe
pneumonia management in intensive care unit (ICU), LOS
ranged from 7.4 to 18.3 days. The mean and median LOS
were 13.7 (95% CI IQR 9.2–18.2) and 14.5 (IQR 10.1–
18.1) days in HIC, and 9.5 (95%CI, 7.4–11.8) and 9.2
(IQR 6.1–12.6) days in LMIC.
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Country, year

Description

Length of stay (SD) in days‡

Sample size

Viet Nam, 2010 [18]

Probable pneumonia
Radiograph confirmed
Probable severe pneumonia
Radiograph confirmed severe pneumonia
Hospital care
Public health care
Private health care
Hospital stay
Antibiotic use duration
National hospitals
District hospitals
District hospitals
District hospitals
Provincial hospitals
Mission Hospitals
Mission Hospitals
Tertiary health center
Time spent at health facility for severe pneumonia
Secondary hospital
In–patient days
Secondary hospital
Tertiary hospital
Tertiary hospital
Public health system
Supplementary health system
Primary
Secondary hospital
Tertiary hospital
Public sector ward
Fee for service sector
Paediatric ward
Non–ICU
Severe pneumonia
Unilateral focal pneumonia without complications
Multifocal pneumonia without complications

7.2 (5.0)
6.7 (3.8)
6.2 (3.3)
6.4 (2.7)
6.0 (5.0–7.0)
7.1
6.4
7.0 (3.0)†
Approx. 8
8.2
6.7
4.8
4.2
6.6
7.8
3.4
4.0
3.3
3.0
4.0–5.0
3.5 (2.9–4.1)
3.7 (3.0–4.4)
6.5 (2.5)
3.9 (2.2)
5.3 (4.7)
2.0 (1.0–2.0)
4.0 (1.0–5.0)
6.0 (3.0–9.0)
8.7
5.6
8.1 (7.4–8.8)
6.7
7.5(8.5)
7.4 (6.0)
8.0 (6.5)
6.4 (4.1–7.1)

40
426
59
193
180
73
41
93
124
49
30
29
17
31
30
19
221
65
502
728
31
25
52
59
20
247
1208
47
86
7786
513
–
42
1994
323

Bangladesh, 2010 [24]
Bangladesh, 2005*
Bangladesh, 2010*
Pakistan, 2003 [25]
Kenya, 2009 [32]

Zambia, 2009 [31]
Pakistan, 2008 [19]
Pakistan, 2006 [20]
Jordan, 2010 [35]
India, 2009 [30]
India, 2002 [29]
Brazil, 2011*
Colombia, 2013 [27]

South Africa, 2011 [33]
South Africa, 2012 [22]
Indonesia, 2001*
Argentina, 2012*

Median (IQR)
ICU – intensive care unit
*Unpublished data.
†Combined HIV+ and HIV–, HIV+ had longer stay in ward (9.3 vs 7.0 days).

‡Length of stay (LOS) reported as mean, mean (standard deviation) or median (interquartile range). When stratified LOS available, then stratified LOS
was reported, not average length of stay of all pneumonia.

demonstrate that choosing the appropriate value for these
inputs will have a significant influence on the total cost.
Existing studies calculated pneumonia management costs
in many countries assuming the same treatment procedure
and unit cost of medicine. However, the cost data we collected demonstrate that this method may have limitations;
the uncertainty in the traditional estimates can be measured
using the cost data reported in this review.

in hospital for severe pneumonia were 1.8–4.6 days less in
LMIC compared to HIC, and at a mean of 5.8 and median
of 6.4 days, were close to the WHO recommendation of 5
days in–patient treatment [10].
We demonstrated that the cost (per episode) for the management of severe pneumonia varied greatly by unit cost of
intervention, disease severity and treatment procedures in
different settings. The review also demonstrated that major
factors governing the total cost per episode were length of
stay in the hospital, countries income level and the presence or absence of community case management for pneumonia. Many other studies have also found GDP per capita to be the main driver of costs [37]. These findings
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Our results showed that direct medical costs for childhood
pneumonia management, especially inpatients, represent a
significant proportion of the average monthly household
income for families in LMICs. This is often compounded
by further direct non–medical cost and indirect cost ie, loss
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Table 7. Length of stay of severe pneumonia in hospital in low– and middle–income countries
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Table 8. Length of stay of very severe and non–severe pneumonia in hospital in low– and middle–income countries
Country, year

VIEWPOINTS
Papers

Very severe pneumonia
Viet Nam, 2010 [18]
Colombia, 2013 [27]
South Africa, 2011 [33]
South Africa, 2012 [22]
Pakistan, 2008 [19]
Argentina, 2012†

Brazil, 2011*
Median (IQR)
Non severe pneumonia
Pakistan, 2008 [19]
South Africa, 2012 [22]
Median (IQR)

Description

Length of stay (SD) days

Sample size

Very severe pneumonia
Confirmed very severe pneumonia
ICU
ICU
ICU
ICU
Time spent at health facility for very severe pneumonia
Very severe pneumonia
Unilateral focal pneumonia without complications
Multifocal pneumonia without complications
Public health system
Supplementary health system

6.4(2.7)
5.8 (3.0)
13.0 (6.0–14.0)
9.4
10.5
14.4(10.3–18.5)
3.9
8.9
17.2
11.5
6.9
6
9.2 (6.1–12.6)

26
44
43
46
93
7
35
–
–
–
–
–

Time spent at health facility for pneumonia
Short stay

0.3
1.4 (1.3–1.6)
0.9 (0.3–1.4)

41
338

ICU – intensive care unit, IQR – interquartile range
*Unpublished data.
†Note added in proof: The data from this study are unpublished but the data on the length of stay are published in Giglio ND, Cane AD, Micone P, Gentile A. Cost-effectiveness of the CRM-based 7-valent pneumococcal conjugated vaccine (PCV7) in Argentina. Vaccine. 2010;28:2302-10. Medline:20064478

Table 9. Chest Radiography cost per episode
Country, year

Cost per episode (US$, 2013)

High income Australia, 2011*
countries
Chile, 2007 [12]
Uruguay, 2007 [12]
United States, 2012*
Mean(SD)
Median(IQR)
Argentina, 2012*
Low– and
middle–
Brazil, 2011*
income
countries
Brazil, 2007 [12]

129.8
135.1
43.4
433.7
185.5 (66.3–357.7)
132.5 (108.2–209.8)
26.7
10.7
6.0
13.63
2.3
5.4
3.2
4.6
2.3
29.7
59.7
137.2
27.7
25.3 (9.8–47.3)
8.4 (4.3–27.0)

Bangladesh, 2010*
India, 2009 [30]
Pakistan, 2008 [19]
Indonesia, 2001*
Kenya, 2009 [32]
South Africa, 2001*
South Africa, 2011 [33]
South Africa, 2012 [22]
Mean (SD)
Median (IQR)

the funds: many borrow or take high–interest loans [26].
Furthermore, Ayieko et al found that 10% of the patients in
district hospitals and up to 25% of children in tertiary hospitals wait in hospital beds after medical discharge while
families source the fees. The latter translates to an additional cost of US$ 17.46 to the public provider and US$ 5.32
to the family [32], resulting in a drain on both the resources of the family and the health care provider, as well as denying a bed to another sick child. It is therefore important
that national strategies for pneumonia management in
LMIC are not only cost–effective for the national program
but also give attention to the burden of costs on families so
that these are maintained at a level that is affordable.
The data in this review comprise “actual” cost data measured
in cost studies conducted in many LMIC and HIC. We believe that these represent a fair first approximation of true
costs in these countries. It is noteworthy that the resulting
cost estimates are higher than those currently contained in
the WHO–CHOICE estimates [38]. Three factors could have
contributed to this variation. First, we identified longer facility and hospital stays compared to standard treatment protocols recommended by the WHO [39]. Moreover, most existing cost studies were conducted at tertiary level hospitals
where out–patient and in–patient treatments carry a much
higher cost compared to the community or first level facility.
Third, the wide variety of antibiotics (including variations in
dosage, route of administration and duration) across the
sites, as well as the heterogeneity in the costing methodology and the cost components in existing studies may have
led to higher estimates.

*Unpublished data.

of earnings when caring for the sick child. In countries
where these families were uninsured, health payments for
pneumonia management were a heavy burden on household and can have a significant impact on the family, particularly when the payments for care were out–of–pocket
in most LMIC countries. Alamgir et al investigated the impact that this strain had on families and how they source
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This review has several limitations. First, the primary goal
of the systematic review was to obtain data on cost of management (per episode) of severe pneumonia. However, the
lack of any standard management protocols (which varied
widely across the included studies) and the general lack of
service uptake data, may have contributed to the substantial
uncertainty around the estimates. Second, we did not include costs of diagnostic investigations in the cost modeling
in some study sites, because country–specific unit prices and
utilization data were not available. Therefore, the true economic burden resulting from the management of childhood
pneumonia could be considerably higher. Third, costs were
highly dependent on level of care offered at facility and LOS
could be skewed to longer period if high level of care (such
as intensive care unit (ICU) care) was offered to severe and
very severe cases. In this review, severe cases were all managed at non–ICU hospital settings, and very severe cases
were managed at both non–ICU and ICU care in hospital
settings. We were able to report LOS separately for non–ICU
and ICU care but this stratification was not possible for total
cost per episode. A further limitation was that the definition
of ICU and ICU care may vary by country. Fourthly, we limited the search to English articles only, which may exclude
some cost reported in other languages, however only 13
studies out of 789 articles in other languages were found.
We tried to compliment this with unpublished data from
non–English speaking countries. Lastly, there was a wide
range in per capita income and health care system and payment schemes within LMIC category and the existing cost
data may only reflect the situation when and where the data
were collected and may not be representative of the whole
country or the current situation. Furthermore, there were
not sufficient studies to address all possible cost scenarios to
facilitate international and public/private comparisons.

Our results demonstrate that further research on the economic burden due to the management of childhood pneumonia is needed, with clear reporting of data on unit cost
of intervention, dosage of various drugs and information
on health care utilization, such as length of stay in hospital.
We recommend that standard reporting of unit cost of intervention with direct medical and non–medical costs and
indirect costs, standard treatment protocols and health resource utilization in conjunction with the total cost per
episode in any cost–of–illness studies would facilitate economic estimates of national scale–up and international
comparisons. Further studies on the cost–effectiveness of
standardized IMCI protocol against other treatment protocols could be expected to find a cost–saving management
strategy for high burden countries.
Identifying the most cost–effective interventions for pneumonia management is essential for achieving the goal of
further reducing child mortality. Our study demonstrated
that early treatment in the community costs less (per event)
than late treatment in the hospital. This finding suggests
that the public health community should explore ways for
community outreach for early diagnosis and treatment before severe pneumonia sets in. The results from this systematic review provide important missing information on
the cost of pneumonia treatment in children across many
countries. These data and the cost estimates should provide
important information useful to program managers and
policy makers at national and regional levels, international
agencies, and donor organisations to aid resource allocation, program planning and priority setting. The estimates
presented in this review could enable a more detailed economic evaluation of the revised WHO pneumonia management guidelines [39], and help identify the most cost–effective preventive and treatment interventions for reducing
the burden of childhood pneumonia.
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